Skip to Main Navigation
Skip to Page Content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it's official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Share This:
https://ntp.niehs.nih.gov/go/14635

TDMS Study 96020-01 Pathology Tables

NTP Experiment-Test: 96020-01         INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a)               Report: PEIRPT03
Study Type: CHRONIC                          TEF EVALUATION (BINARY MIXTURE; PCB 126/PCB 153)                     Date: 03/03/04
Route: GAVAGE                                                                                                     Time: 09:43:49

                                                            FINAL #1




       Facility:  Battelle Columbus Laboratory

       Chemical CAS #:  TEFBINARYMIX

       Lock Date:  03/27/02

       Cage Range:  All

       Reasons For Removal:    25018 Dosing Accident                   25019 Moribund Sacrifice
                               25020 Natural Death                     25021 Terminal Sacrifice

       Removal Date Range:     All

       Treatment Groups:       Include 001    0 NG /  0 UG
                               Include 002    10 NG / 10 UG
                               Include 003    100 NG /100 UG
                               Include 005    300 NG /300 UG
                               Include 007    1000 NG/1000 UG





























a  Number of animals examined microscopically at site and number of animals with lesion

                                                              Page   1


NTP Experiment-Test: 96020-01         INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a)               Report: PEIRPT03  
Study Type: CHRONIC                          TEF EVALUATION (BINARY MIXTURE; PCB 126/PCB 153)                     Date: 03/03/04    
Route: GAVAGE                                                                                                     Time: 09:43:49    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         SPRAGUE-DAWLEY RATS FEMALE                0 NG /       10 NG /      100 NG /     300 NG /     1000 NG/                     
                                                   0 UG         10 UG        100 UG       300 UG       1000 UG                      
____________________________________________________________________________________________________________________________________
                                                                                                                                    
DISPOSITION SUMMARY                                                                                                                 
                                                                                                                                    
  Animals Initially In Study                          98           86           98           98           98                        
  Early Deaths                                                                                                                      
    Moribund Sacrifice                                22           19           24           19           20                        
    Natural Death                                      8           12            6           10            7                        
    Dosing Accident                                    1            1            1                         2                        
  Survivors                                                                                                                         
    Terminal Sacrifice                                22           21           22           24           24                        
                                                                                                                                    
  Animals Examined Microscopically                    53           53           53           53           53                        
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 ALIMENTARY SYSTEM                                                                                                                  
                                                                                                                                    
   Esophagus                                          (53)         (53)         (52)         (53)         (52)                      
      Cyst                                                                                                 1 (2%)                   
      Perforation                                                                1 (2%)                    2 (4%)                   
      Muscularis, Inflammation                         3 (6%)       1 (2%)       1 (2%)       3 (6%)       3 (6%)                   
      Periesophageal Tissue, Hemorrhage                                                                    1 (2%)                   
      Periesophageal Tissue, Inflammation                                        1 (2%)                    1 (2%)                   
   Intestine Large, Colon                             (53)         (53)         (53)         (52)         (49)                      
      Hyperplasia, Lymphoid                                                      1 (2%)                                             
      Parasite Metazoan                                             2 (4%)                                                          
   Intestine Large, Rectum                            (53)         (53)         (53)         (53)         (50)                      
      Metaplasia, Squamous                                                                                 1 (2%)                   
      Parasite Metazoan                                2 (4%)                                 1 (2%)       3 (6%)                   
   Intestine Large, Cecum                             (53)         (53)         (53)         (52)         (49)                      
      Mineralization                                                             1 (2%)                                             
   Intestine Small, Jejunum                           (53)         (53)         (52)         (52)         (49)                      
      Hyperplasia, Lymphoid                                                      1 (2%)       2 (4%)       1 (2%)                   
      Ulcer                                                                                   1 (2%)                                
   Intestine Small, Ileum                             (53)         (53)         (52)         (52)         (49)                      
      Hyperplasia, Lymphoid                            1 (2%)                                                                       
   Liver                                              (53)         (53)         (52)         (52)         (51)                      
      Angiectasis                                      3 (6%)       1 (2%)       1 (2%)       2 (4%)       5 (10%)                  
      Basophilic Focus                                 9 (17%)      7 (13%)      8 (15%)      2 (4%)       3 (6%)                   
      Basophilic Focus, Multiple                      13 (25%)     15 (28%)      6 (12%)      1 (2%)       3 (6%)                   
      Cholangiofibrosis                                             1 (2%)                    7 (13%)     39 (76%)                  
      Clear Cell Focus                                 3 (6%)       2 (4%)       2 (4%)       3 (6%)       1 (2%)                   
      Clear Cell Focus, Multiple                       6 (11%)      1 (2%)       1 (2%)                                             
      Eosinophilic Focus                               7 (13%)      8 (15%)      4 (8%)       7 (13%)      1 (2%)                   
      Eosinophilic Focus, Multiple                     7 (13%)      8 (15%)     26 (50%)     33 (63%)     17 (33%)                  
      Fatty Change, Diffuse                            3 (6%)       1 (2%)       9 (17%)     31 (60%)     38 (75%)                  
                                                                                                                                    
a  Number of animals examined microscopically at site and number of animals with lesion                                             
                                                                                                                                    
                                                             Page    2                                                              
                                                                                                                                   
NTP Experiment-Test: 96020-01         INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a)               Report: PEIRPT03  
Study Type: CHRONIC                          TEF EVALUATION (BINARY MIXTURE; PCB 126/PCB 153)                     Date: 03/03/04    
Route: GAVAGE                                                                                                     Time: 09:43:49    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         SPRAGUE-DAWLEY RATS FEMALE                0 NG /       10 NG /      100 NG /     300 NG /     1000 NG/                     
                                                   0 UG         10 UG        100 UG       300 UG       1000 UG                      
____________________________________________________________________________________________________________________________________
                                                                                                                                    
ALIMENTARY SYSTEM - CONT                                                                                                            
      Fatty Change, Focal                              3 (6%)       4 (8%)       7 (13%)      1 (2%)      12 (24%)                  
      Hematopoietic Cell Proliferation                27 (51%)     29 (55%)     30 (58%)     19 (37%)     11 (22%)                  
      Hepatodiaphragmatic Nodule                                    2 (4%)                                                          
      Hyperplasia, Nodular                                                       2 (4%)      24 (46%)     42 (82%)                  
      Inflammation                                    44 (83%)     41 (77%)     46 (88%)     48 (92%)     46 (90%)                  
      Metaplasia                                                                                           1 (2%)                   
      Mixed Cell Focus                                 7 (13%)      3 (6%)       4 (8%)       2 (4%)       1 (2%)                   
      Mixed Cell Focus, Multiple                      19 (36%)     19 (36%)     26 (50%)     24 (46%)      2 (4%)                   
      Necrosis                                         4 (8%)       8 (15%)      5 (10%)      4 (8%)      20 (39%)                  
      Pigmentation                                     2 (4%)       5 (9%)      38 (73%)     50 (96%)     50 (98%)                  
      Toxic Hepatopathy                                             2 (4%)      34 (65%)     48 (92%)     49 (96%)                  
      Bile Duct, Cyst                                  4 (8%)       3 (6%)       1 (2%)       5 (10%)     23 (45%)                  
      Bile Duct, Dilatation                                         1 (2%)                                                          
      Bile Duct, Fibrosis                              1 (2%)       3 (6%)       3 (6%)       4 (8%)                                
      Bile Duct, Hyperplasia                           8 (15%)      2 (4%)       9 (17%)     29 (56%)     46 (90%)                  
      Centrilobular, Degeneration                      5 (9%)       7 (13%)      2 (4%)       4 (8%)       3 (6%)                   
      Centrilobular, Fibrosis                                                                 1 (2%)       1 (2%)                   
      Hepatocyte, Hypertrophy                          1 (2%)       7 (13%)     17 (33%)     33 (63%)     50 (98%)                  
      Hepatocyte, Multinucleated                                                14 (27%)     46 (88%)     48 (94%)                  
      Oval Cell, Hyperplasia                           2 (4%)       2 (4%)      15 (29%)     39 (75%)     46 (90%)                  
      Portal, Fibrosis                                                                        7 (13%)     34 (67%)                  
      Serosa, Inflammation, Chronic Active             1 (2%)                                                                       
   Mesentery                                          (47)         (47)         (46)         (47)         (42)                      
      Artery, Inflammation, Chronic Active             1 (2%)       1 (2%)       1 (2%)       2 (4%)       4 (10%)                  
      Fat, Necrosis                                                 2 (4%)       2 (4%)       1 (2%)                                
   Oral Mucosa                                        (12)         (11)         (25)         (30)         (36)                      
      Gingival, Hyperplasia, Squamous                  8 (67%)      8 (73%)     18 (72%)     22 (73%)     24 (67%)                  
      Pharyngeal, Inflammation                                                                             1 (3%)                   
   Pancreas                                           (53)         (53)         (52)         (52)         (50)                      
      Inflammation, Chronic Active                                  3 (6%)       3 (6%)       1 (2%)       4 (8%)                   
      Acinus, Atrophy                                               2 (4%)       1 (2%)       1 (2%)       8 (16%)                  
      Acinus, Hyperplasia                              2 (4%)                                 1 (2%)                                
      Acinus, Vacuolization Cytoplasmic                                                       7 (13%)     40 (80%)                  
      Artery, Inflammation, Chronic Active                                       1 (2%)       2 (4%)       2 (4%)                   
      Duct, Dilatation                                                                                     1 (2%)                   
   Salivary Glands                                    (53)         (51)         (52)         (50)         (52)                      
      Inflammation, Chronic Active                                               1 (2%)                                             
   Stomach, Forestomach                               (53)         (53)         (52)         (52)         (51)                      
      Hyperkeratosis                                                             1 (2%)       2 (4%)                                
      Hyperplasia, Squamous                            1 (2%)       1 (2%)       2 (4%)       7 (13%)      8 (16%)                  
      Inflammation                                                               1 (2%)       1 (2%)                                
      Mineralization                                   1 (2%)       1 (2%)                                                          
      Ulcer                                                                      1 (2%)       2 (4%)       1 (2%)                   
                                                                                                                                    
a  Number of animals examined microscopically at site and number of animals with lesion                                             
                                                                                                                                    
                                                             Page    3                                                              
                                                                                                                                   
NTP Experiment-Test: 96020-01         INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a)               Report: PEIRPT03  
Study Type: CHRONIC                          TEF EVALUATION (BINARY MIXTURE; PCB 126/PCB 153)                     Date: 03/03/04    
Route: GAVAGE                                                                                                     Time: 09:43:49    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         SPRAGUE-DAWLEY RATS FEMALE                0 NG /       10 NG /      100 NG /     300 NG /     1000 NG/                     
                                                   0 UG         10 UG        100 UG       300 UG       1000 UG                      
____________________________________________________________________________________________________________________________________
                                                                                                                                    
ALIMENTARY SYSTEM - CONT                                                                                                            
   Stomach, Glandular                                 (53)         (53)         (52)         (52)         (51)                      
      Cyst                                                                                                 1 (2%)                   
      Ectopic Tissue                                                                          1 (2%)                                
      Erosion                                                                                 1 (2%)       2 (4%)                   
      Inflammation, Chronic Active                                               1 (2%)                                             
      Mineralization                                   4 (8%)       3 (6%)       3 (6%)       1 (2%)                                
      Ulcer                                                                      1 (2%)                                             
   Tooth                                              (23)         (14)         (33)         (35)         (31)                      
      Peridontal Tissue, Inflammation                 23 (100%)    14 (100%)    33 (100%)    35 (100%)    31 (100%)                 
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 CARDIOVASCULAR SYSTEM                                                                                                              
                                                                                                                                    
   Blood Vessel                                       (53)         (53)         (52)         (53)         (52)                      
      Aorta, Mineralization                                                                   1 (2%)                                
   Heart                                              (53)         (52)         (52)         (53)         (52)                      
      Cardiomyopathy                                  22 (42%)     19 (37%)     22 (42%)     26 (49%)     15 (29%)                  
      Fibrosis                                                                                             1 (2%)                   
      Hemorrhage                                                                                           1 (2%)                   
      Inflammation, Chronic Active                     1 (2%)                                              1 (2%)                   
      Thrombosis                                                                                           1 (2%)                   
      Coronary Artery, Inflammation, Chronic Active                              1 (2%)                    6 (12%)                  
      Pericardium, Necrosis                                                                   1 (2%)                                
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 ENDOCRINE SYSTEM                                                                                                                   
                                                                                                                                    
   Adrenal Cortex                                     (53)         (53)         (52)         (52)         (51)                      
      Angiectasis                                     17 (32%)     26 (49%)     33 (63%)     23 (44%)      5 (10%)                  
      Atrophy                                                                                 3 (6%)      35 (69%)                  
      Degeneration, Cystic                            13 (25%)     12 (23%)     13 (25%)     14 (27%)     16 (31%)                  
      Hematopoietic Cell Proliferation                 1 (2%)                                                                       
      Hyperplasia                                     11 (21%)     18 (34%)     23 (44%)     25 (48%)     18 (35%)                  
      Hypertrophy                                     47 (89%)     38 (72%)     44 (85%)     41 (79%)     32 (63%)                  
      Necrosis                                         1 (2%)                                              1 (2%)                   
      Vacuolization Cytoplasmic                       11 (21%)     12 (23%)     14 (27%)     10 (19%)     13 (25%)                  
   Adrenal Medulla                                    (52)         (53)         (52)         (52)         (51)                      
      Hyperplasia                                     15 (29%)     13 (25%)     14 (27%)     13 (25%)      3 (6%)                   
   Islets, Pancreatic                                 (53)         (53)         (52)         (52)         (50)                      
      Hyperplasia                                                                1 (2%)                                             
   Parathyroid Gland                                  (45)         (47)         (46)         (47)         (46)                      
      Hyperplasia                                                   1 (2%)                                                          
   Pituitary Gland                                    (53)         (53)         (53)         (52)         (52)                      
                                                                                                                                    
a  Number of animals examined microscopically at site and number of animals with lesion                                             
                                                                                                                                    
                                                             Page    4                                                              
                                                                                                                                   
NTP Experiment-Test: 96020-01         INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a)               Report: PEIRPT03  
Study Type: CHRONIC                          TEF EVALUATION (BINARY MIXTURE; PCB 126/PCB 153)                     Date: 03/03/04    
Route: GAVAGE                                                                                                     Time: 09:43:49    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         SPRAGUE-DAWLEY RATS FEMALE                0 NG /       10 NG /      100 NG /     300 NG /     1000 NG/                     
                                                   0 UG         10 UG        100 UG       300 UG       1000 UG                      
____________________________________________________________________________________________________________________________________
                                                                                                                                    
ENDOCRINE SYSTEM - CONT                                                                                                             
      Angiectasis                                     17 (32%)     20 (38%)     15 (28%)     17 (33%)      1 (2%)                   
      Cyst                                             1 (2%)       3 (6%)                                                          
      Cytoplasmic Alteration                                                     3 (6%)                                             
      Inflammation                                                                            1 (2%)                                
      Vacuolization Cytoplasmic                                                               1 (2%)                                
      Pars Distalis, Hyperplasia                      13 (25%)     13 (25%)     19 (36%)     20 (38%)     13 (25%)                  
      Pars Intermedia, Hyperplasia                                                                         2 (4%)                   
   Thyroid Gland                                      (53)         (53)         (51)         (52)         (52)                      
      C-Cell, Hyperplasia                             15 (28%)     19 (36%)     22 (43%)     12 (23%)     15 (29%)                  
      Follicle, Cyst                                   2 (4%)                                                                       
      Follicular Cell, Hypertrophy                    14 (26%)     17 (32%)     34 (67%)     35 (67%)     42 (81%)                  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 GENERAL BODY SYSTEM                                                                                                                
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 GENITAL SYSTEM                                                                                                                     
                                                                                                                                    
   Clitoral Gland                                     (53)         (53)         (53)         (53)         (50)                      
      Inflammation                                    45 (85%)     49 (92%)     46 (87%)     40 (75%)     23 (46%)                  
      Duct, Cyst                                      38 (72%)     40 (75%)     48 (91%)     43 (81%)     43 (86%)                  
   Ovary                                              (53)         (53)         (52)         (52)         (49)                      
      Atrophy                                         45 (85%)     44 (83%)     45 (87%)     43 (83%)     16 (33%)                  
      Cyst                                            14 (26%)      7 (13%)     17 (33%)     14 (27%)     13 (27%)                  
      Inflammation, Chronic Active                     1 (2%)       1 (2%)                                 1 (2%)                   
      Inflammation, Suppurative                                                               1 (2%)                                
   Oviduct                                            (1)                       (1)          (2)          (3)                       
      Cyst                                             1 (100%)                  1 (100%)     2 (100%)                              
      Inflammation, Chronic Active                                               1 (100%)                  3 (100%)                 
   Uterus                                             (53)         (53)         (53)         (52)         (50)                      
      Adenomyosis                                                                1 (2%)                    1 (2%)                   
      Hemorrhage                                                                                           1 (2%)                   
      Hyperplasia                                                   1 (2%)                                                          
      Inflammation, Chronic Active                     3 (6%)                    1 (2%)       7 (13%)      2 (4%)                   
      Inflammation, Suppurative                        3 (6%)       5 (9%)       8 (15%)     10 (19%)      5 (10%)                  
      Metaplasia, Squamous                            27 (51%)     30 (57%)     35 (66%)     36 (69%)     14 (28%)                  
      Ulcer                                                                                                1 (2%)                   
      Endometrium, Hyperplasia, Cystic                28 (53%)     23 (43%)     34 (64%)     18 (35%)     12 (24%)                  
   Vagina                                             (1)          (1)          (1)          (1)                                    
      Inflammation                                                               1 (100%)                                           
____________________________________________________________________________________________________________________________________
                                                                                                                                    
a  Number of animals examined microscopically at site and number of animals with lesion                                             
                                                                                                                                    
                                                             Page    5                                                              
                                                                                                                                   
NTP Experiment-Test: 96020-01         INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a)               Report: PEIRPT03  
Study Type: CHRONIC                          TEF EVALUATION (BINARY MIXTURE; PCB 126/PCB 153)                     Date: 03/03/04    
Route: GAVAGE                                                                                                     Time: 09:43:49    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         SPRAGUE-DAWLEY RATS FEMALE                0 NG /       10 NG /      100 NG /     300 NG /     1000 NG/                     
                                                   0 UG         10 UG        100 UG       300 UG       1000 UG                      
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
 HEMATOPOIETIC SYSTEM                                                                                                               
                                                                                                                                    
   Bone Marrow                                        (53)         (53)         (53)         (53)         (53)                      
      Atrophy                                                       1 (2%)                                                          
      Degeneration                                                               1 (2%)                                             
      Hyperplasia                                     39 (74%)     38 (72%)     42 (79%)     48 (91%)     49 (92%)                  
   Lymph Node                                         (4)          (7)          (2)          (7)          (14)                      
      Angiectasis                                                                             1 (14%)      1 (7%)                   
      Inguinal, Hyperplasia, Plasma Cell                                                      1 (14%)                               
      Lumbar, Ectasia                                  4 (100%)     4 (57%)                   1 (14%)                               
      Lumbar, Hemorrhage                                            2 (29%)                                                         
      Lumbar, Hyperplasia                                           1 (14%)                                                         
      Lumbar, Hyperplasia, Plasma Cell                 4 (100%)     1 (14%)                                                         
      Mediastinal, Ectasia                                                                                 3 (21%)                  
      Mediastinal, Hemorrhage                                                                 1 (14%)      2 (14%)                  
      Mediastinal, Hyperplasia, Histiocytic                         1 (14%)                   1 (14%)      3 (21%)                  
      Mediastinal, Hyperplasia, Lymphoid                            1 (14%)                                                         
      Mediastinal, Hyperplasia, Plasma Cell                                                                2 (14%)                  
      Pancreatic, Hyperplasia, Histiocytic                                                    1 (14%)      3 (21%)                  
      Pancreatic, Hyperplasia, Plasma Cell                                                                 1 (7%)                   
      Pancreatic, Pigmentation                                                                1 (14%)      1 (7%)                   
      Renal, Ectasia                                                1 (14%)      1 (50%)      1 (14%)      1 (7%)                   
      Renal, Hemorrhage                                                          1 (50%)                                            
      Renal, Hyperplasia, Histiocytic                                                         1 (14%)      2 (14%)                  
      Renal, Hyperplasia, Lymphoid                                                                         1 (7%)                   
      Renal, Hyperplasia, Plasma Cell                               1 (14%)                   1 (14%)                               
   Lymph Node, Mandibular                             (53)         (51)         (52)         (50)         (51)                      
      Congestion                                                                              1 (2%)                                
      Ectasia                                                       3 (6%)       6 (12%)      3 (6%)       6 (12%)                  
      Hemorrhage                                                    1 (2%)                                 1 (2%)                   
      Hyperplasia, Lymphoid                            1 (2%)       2 (4%)       3 (6%)       2 (4%)       5 (10%)                  
      Hyperplasia, Plasma Cell                        37 (70%)     37 (73%)     40 (77%)     36 (72%)     31 (61%)                  
   Lymph Node, Mesenteric                             (53)         (53)         (52)         (52)         (49)                      
      Hemorrhage                                                                              1 (2%)                                
      Hyperplasia, Histiocytic                                                                1 (2%)       2 (4%)                   
      Hyperplasia, Lymphoid                                                      1 (2%)                    1 (2%)                   
      Inflammation, Chronic Active                                               1 (2%)                                             
   Spleen                                             (53)         (53)         (52)         (52)         (50)                      
      Fibrosis                                                                                1 (2%)                                
      Hematopoietic Cell Proliferation                51 (96%)     51 (96%)     49 (94%)     47 (90%)     44 (88%)                  
      Hyperplasia                                                                1 (2%)                                             
      Pigmentation                                    47 (89%)     46 (87%)     43 (83%)     51 (98%)     46 (92%)                  
      Lymphoid Follicle, Atrophy                                                 2 (4%)       4 (8%)       5 (10%)                  
                                                                                                                                    
a  Number of animals examined microscopically at site and number of animals with lesion                                             
                                                                                                                                    
                                                             Page    6                                                              
                                                                                                                                   
NTP Experiment-Test: 96020-01         INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a)               Report: PEIRPT03  
Study Type: CHRONIC                          TEF EVALUATION (BINARY MIXTURE; PCB 126/PCB 153)                     Date: 03/03/04    
Route: GAVAGE                                                                                                     Time: 09:43:49    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         SPRAGUE-DAWLEY RATS FEMALE                0 NG /       10 NG /      100 NG /     300 NG /     1000 NG/                     
                                                   0 UG         10 UG        100 UG       300 UG       1000 UG                      
____________________________________________________________________________________________________________________________________
                                                                                                                                    
HEMATOPOIETIC SYSTEM - CONT                                                                                                         
      Red Pulp, Atrophy                                1 (2%)                    1 (2%)                    5 (10%)                  
   Thymus                                             (53)         (50)         (48)         (50)         (51)                      
      Atrophy                                         33 (62%)     33 (66%)     43 (90%)     42 (84%)     49 (96%)                  
      Cyst                                                                                    1 (2%)                                
      Hemorrhage                                       1 (2%)                                 3 (6%)       1 (2%)                   
      Hyperplasia, Lymphoid                            2 (4%)                                                                       
      Inflammation                                                                                         1 (2%)                   
      Epithelial Cell, Hyperplasia                                                            1 (2%)                                
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 INTEGUMENTARY SYSTEM                                                                                                               
                                                                                                                                    
   Mammary Gland                                      (53)         (53)         (52)         (53)         (52)                      
      Cyst                                             3 (6%)       2 (4%)       2 (4%)       3 (6%)       1 (2%)                   
      Hyperplasia                                     29 (55%)     29 (55%)     25 (48%)     22 (42%)      3 (6%)                   
      Inflammation, Granulomatous                      5 (9%)                    4 (8%)       3 (6%)                                
      Duct, Cyst                                       1 (2%)                                                                       
   Skin                                               (53)         (53)         (53)         (53)         (53)                      
      Angiectasis                                      1 (2%)                                                                       
      Cyst Epithelial Inclusion                                                               1 (2%)                                
      Fibrosis                                         1 (2%)                                                                       
      Inflammation                                                               1 (2%)                    1 (2%)                   
      Ulcer                                                                      2 (4%)                    1 (2%)                   
      Dermis, Fibrosis                                                           1 (2%)                                             
      Epidermis, Hyperplasia                                                     1 (2%)                                             
      Subcutaneous Tissue, Inflammation                                          1 (2%)                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 MUSCULOSKELETAL SYSTEM                                                                                                             
                                                                                                                                    
   Skeletal Muscle                                    (1)          (1)                       (1)          (1)                       
      Hemorrhage                                                                                           1 (100%)                 
      Inflammation                                                                                         1 (100%)                 
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 NERVOUS SYSTEM                                                                                                                     
                                                                                                                                    
   Brain                                              (53)         (53)         (53)         (52)         (52)                      
      Hemorrhage                                                                 1 (2%)       1 (2%)                                
      Hydrocephalus                                    1 (2%)                                                                       
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
a  Number of animals examined microscopically at site and number of animals with lesion                                             
                                                                                                                                    
                                                                                                                                    
                                                             Page    7                                                              
                                                                                                                                   
NTP Experiment-Test: 96020-01         INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a)               Report: PEIRPT03  
Study Type: CHRONIC                          TEF EVALUATION (BINARY MIXTURE; PCB 126/PCB 153)                     Date: 03/03/04    
Route: GAVAGE                                                                                                     Time: 09:43:49    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         SPRAGUE-DAWLEY RATS FEMALE                0 NG /       10 NG /      100 NG /     300 NG /     1000 NG/                     
                                                   0 UG         10 UG        100 UG       300 UG       1000 UG                      
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 RESPIRATORY SYSTEM                                                                                                                 
                                                                                                                                    
   Lung                                               (53)         (53)         (52)         (53)         (52)                      
      Hemorrhage                                                                 1 (2%)                                             
      Infiltration Cellular, Histiocyte               47 (89%)     41 (77%)     47 (90%)     46 (87%)     45 (87%)                  
      Inflammation                                     8 (15%)      5 (9%)       2 (4%)       4 (8%)       1 (2%)                   
      Metaplasia, Squamous                                                       1 (2%)       2 (4%)      11 (21%)                  
      Mineralization                                                1 (2%)                    1 (2%)                                
      Alveolar Epithelium, Hyperplasia                23 (43%)     20 (38%)     17 (33%)      5 (9%)       5 (10%)                  
      Alveolar Epithelium, Metaplasia, Bronchiolar                  6 (11%)     23 (44%)     34 (64%)     32 (62%)                  
      Bronchiole, Hyperplasia                                                                              1 (2%)                   
      Mediastinum, Hemorrhage                                                                              1 (2%)                   
      Mediastinum, Necrosis                                                                   1 (2%)                                
      Serosa, Inflammation                                                                    1 (2%)                                
   Nose                                               (53)         (53)         (53)         (53)         (53)                      
      Hyperplasia                                                                                          1 (2%)                   
      Inflammation                                    22 (42%)     13 (25%)     13 (25%)     13 (25%)     31 (58%)                  
      Glands, Hyperplasia                                                                                  8 (15%)                  
      Olfactory Epithelium, Degeneration               1 (2%)                                              2 (4%)                   
      Olfactory Epithelium, Metaplasia                 4 (8%)       3 (6%)       5 (9%)       6 (11%)     15 (28%)                  
      Respiratory Epithelium, Hyperplasia             10 (19%)      5 (9%)       7 (13%)     11 (21%)     20 (38%)                  
      Respiratory Epithelium, Metaplasia               1 (2%)                                                                       
      Respiratory Epithelium, Vacuolization                                                                                         
        Cytoplasmic                                                 1 (2%)                                                          
   Trachea                                            (53)         (53)         (52)         (53)         (52)                      
      Inflammation                                     1 (2%)                                                                       
      Peritracheal Tissue, Hemorrhage                                                                      1 (2%)                   
      Peritracheal Tissue, Inflammation                                                                    1 (2%)                   
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 SPECIAL SENSES SYSTEM                                                                                                              
                                                                                                                                    
   Eye                                                (53)         (53)         (53)         (52)         (52)                      
      Anterior Chamber, Ciliary Body, Cornea,                                                                                       
        Inflammation                                                                          1 (2%)       3 (6%)                   
      Cornea, Inflammation                                                                    1 (2%)                                
      Retina, Atrophy                                  1 (2%)       3 (6%)       4 (8%)       2 (4%)       5 (10%)                  
   Harderian Gland                                    (53)         (53)         (53)         (52)         (52)                      
      Inflammation                                    20 (38%)     14 (26%)     16 (30%)     14 (27%)     16 (31%)                  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 URINARY SYSTEM                                                                                                                     
                                                                                                                                    
   Kidney                                             (53)         (53)         (52)         (52)         (51)                      
                                                                                                                                    
a  Number of animals examined microscopically at site and number of animals with lesion                                             
                                                                                                                                    
                                                             Page    8                                                              
                                                                                                                                   
NTP Experiment-Test: 96020-01         INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a)               Report: PEIRPT03  
Study Type: CHRONIC                          TEF EVALUATION (BINARY MIXTURE; PCB 126/PCB 153)                     Date: 03/03/04    
Route: GAVAGE                                                                                                     Time: 09:43:49    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         SPRAGUE-DAWLEY RATS FEMALE                0 NG /       10 NG /      100 NG /     300 NG /     1000 NG/                     
                                                   0 UG         10 UG        100 UG       300 UG       1000 UG                      
____________________________________________________________________________________________________________________________________
                                                                                                                                    
URINARY SYSTEM - CONT                                                                                                               
      Accumulation, Hyaline Droplet                    2 (4%)                    1 (2%)       1 (2%)       1 (2%)                   
      Calculus Gross Observation                                    1 (2%)                                                          
      Calculus Micro Observation Only                  7 (13%)      4 (8%)       1 (2%)       4 (8%)       1 (2%)                   
      Casts Protein                                    2 (4%)       1 (2%)                                                          
      Cyst                                                          1 (2%)       1 (2%)       1 (2%)                                
      Infarct                                                                    1 (2%)                    1 (2%)                   
      Inflammation, Chronic Active                     1 (2%)       1 (2%)                    1 (2%)       1 (2%)                   
      Inflammation, Suppurative                        5 (9%)       3 (6%)       1 (2%)       5 (10%)      1 (2%)                   
      Mineralization                                  42 (79%)     38 (72%)     39 (75%)     42 (81%)     35 (69%)                  
      Necrosis                                                                   1 (2%)                                             
      Nephropathy                                     29 (55%)     22 (42%)     29 (56%)     34 (65%)     43 (84%)                  
      Pigmentation                                                  1 (2%)       3 (6%)       7 (13%)     35 (69%)                  
      Pelvis, Dilatation                               1 (2%)                                 2 (4%)       1 (2%)                   
      Pelvis, Inflammation                             3 (6%)                    4 (8%)       3 (6%)       5 (10%)                  
      Renal Tubule, Degeneration                                                 1 (2%)       2 (4%)       1 (2%)                   
      Transitional Epithelium, Hyperplasia             2 (4%)       2 (4%)       4 (8%)      11 (21%)      6 (12%)                  
   Ureter                                             (1)          (1)                       (1)          (1)                       
      Inflammation                                     1 (100%)                               1 (100%)                              
      Mineralization                                                                                       1 (100%)                 
      Transitional Epithelium, Hyperplasia             1 (100%)                                            1 (100%)                 
   Urinary Bladder                                    (53)         (53)         (53)         (52)         (50)                      
      Inflammation                                     7 (13%)      8 (15%)      5 (9%)       7 (13%)                               
      Transitional Epithelium, Hyperplasia                                                    1 (2%)                                
                                                                                                                                    
                                                                                                                                    
a  Number of animals examined microscopically at site and number of animals with lesion                                             
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page    9                                                              
                                                                                                                                   
                             ------------------------------------------------------------                                           
                             ----------              END OF REPORT             ----------                                           
                             ------------------------------------------------------------